- Home
- BFZ vs RIGL Comparison
BFZ vs RIGL Comparison
Compare BFZ & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFZ
- RIGL
- Stock Information
- Founded
- BFZ 2001
- RIGL 1996
- Country
- BFZ United States
- RIGL United States
- Employees
- BFZ N/A
- RIGL N/A
- Industry
- BFZ Finance Companies
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- BFZ Finance
- RIGL Health Care
- Exchange
- BFZ Nasdaq
- RIGL Nasdaq
- Market Cap
- BFZ 315.1M
- RIGL 335.5M
- IPO Year
- BFZ N/A
- RIGL 2000
- Fundamental
- Price
- BFZ $10.40
- RIGL $38.85
- Analyst Decision
- BFZ
- RIGL Buy
- Analyst Count
- BFZ 0
- RIGL 5
- Target Price
- BFZ N/A
- RIGL $38.20
- AVG Volume (30 Days)
- BFZ 60.7K
- RIGL 995.6K
- Earning Date
- BFZ 01-01-0001
- RIGL 08-05-2025
- Dividend Yield
- BFZ 4.39%
- RIGL N/A
- EPS Growth
- BFZ N/A
- RIGL N/A
- EPS
- BFZ 0.08
- RIGL 5.43
- Revenue
- BFZ N/A
- RIGL $267,921,000.00
- Revenue This Year
- BFZ N/A
- RIGL $59.93
- Revenue Next Year
- BFZ N/A
- RIGL N/A
- P/E Ratio
- BFZ $147.26
- RIGL $7.15
- Revenue Growth
- BFZ N/A
- RIGL 105.62
- 52 Week Low
- BFZ $9.86
- RIGL $12.66
- 52 Week High
- BFZ $12.31
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- BFZ 37.41
- RIGL 68.57
- Support Level
- BFZ $10.55
- RIGL $39.00
- Resistance Level
- BFZ $10.44
- RIGL $42.08
- Average True Range (ATR)
- BFZ 0.08
- RIGL 2.32
- MACD
- BFZ -0.00
- RIGL -0.37
- Stochastic Oscillator
- BFZ 21.59
- RIGL 53.26
About BFZ BlackRock California Municipal Income Trust
Blackrock CA Muni Income Tr is a United States-based closed-end management investment company. The investment objective of the trust is to provide current income exempt from regular U.S. federal income tax. The trust seeks to achieve its investment objectives by investing a majority of its total assets in municipal bonds.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.